Clinical Trials Logo

Malignant Melanoma Stage IV clinical trials

View clinical trials related to Malignant Melanoma Stage IV.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02439411 Completed - Clinical trials for Malignant Melanoma Stage IV

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

DEIS
Start date: March 3, 2015
Phase:
Study type: Observational

The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.

NCT ID: NCT01983124 Completed - Clinical trials for Malignant Melanoma Stage IV

Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib

BeyPro1
Start date: February 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity of Vemurafenib in combination with Fotemustine in Patients with unresectable Stage IV melanoma harboring V600 BRAF mutation who recurred while in treatment with Vemurafenib. In addition the feasibility and safety profile of prolonging treatment of this drugs combination will be assessed.

NCT ID: NCT01676779 Completed - Clinical trials for Malignant Melanoma Stage IV

mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma

DC-MEL
Start date: October 2012
Phase: Phase 2
Study type: Interventional

This is an open label, 2-arm, 1-stage, randomized controlled phase II study in patients with AJCC stage IIIB/C & -IV melanoma. At baseline tumor assessment (using total body FDG-PET/CT), patients should be free from measurable tumor lesions (according to RECISTv1.1 definitions) following prior local therapy (e.g. following surgical resection, isolated limb perfusion, radiofrequency ablation, cryotherapy, radiotherapy, electrochemotherapy, …). Patients should not have symptomatic non-measurable tumor lesions (e.g. bone metastasis, or pleural effusion), and lesions treated by prior local therapy should be free from progression. Patients should not have received any prior systemic therapy (non-experimental or experimental).

NCT ID: NCT01302496 Completed - Clinical trials for Malignant Melanoma Stage IV

Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma

TriMix-Ipi
Start date: February 2011
Phase: Phase 2
Study type: Interventional

The CTLA-4 blocking monoclonal antibody ipilimumab (MDX-010, BMS-734016), has demonstrated anti-tumor activity in a subgroup of patients with Stage III (unresectable) or Stage IV melanoma (measurable per modified WHO criteria), who have received prior treatment with any regimen (non-experimental or experimental), except a CD-137 agonist or a CTLA4 inhibitor or agonist and relapsed, failed to respond (CR or PR) or did not tolerate that regimen (Wolchok, Neyns et al. 2009; O'Day, Maio et al. 2010). Ipilimumab exerts its therapeutic effect presumably by activating T-lymphocytes that infiltrate the tumor mass to destroy the malignant cells by mechanisms of cytotoxic cellular interaction. Autologous TriMix-DC vaccine can induce a T-cell repertoire that recognizes in a HLA-restricted way the melanoma associated antigens MAGE-A3, MAGE-C2, tyrosinase and gp100. Administration of ipilimumab together with TriMix-DC vaccine therapy may be a more effective treatment for patients with advanced melanoma as compared to either modality alone.

NCT ID: NCT01189383 Completed - Clinical trials for Malignant Melanoma Stage IV

IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma

NCT ID: NCT00313235 Completed - Clinical trials for Malignant Melanoma Stage IV

Combined Modality Treatment for Patients With Stage IV Melanoma

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test a combined treatment using cyclophosphamide and a novel dendritic cell vaccine in patients with Stage IV melanoma.